Follistatin-288-Fc Fusion Protein Promotes Localized Growth of Skeletal Muscle.


Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
03 2019
Historique:
received: 30 07 2018
accepted: 06 12 2018
pubmed: 20 12 2018
medline: 2 11 2019
entrez: 20 12 2018
Statut: ppublish

Résumé

Follistatin is an endogenous glycoprotein that promotes growth and repair of skeletal muscle by sequestering inhibitory ligands of the transforming growth factor-

Identifiants

pubmed: 30563942
pii: jpet.118.252304
doi: 10.1124/jpet.118.252304
doi:

Substances chimiques

Follistatin 0
Immunoglobulin G 0
Recombinant Fusion Proteins 0
follistatin, 288-amino acid isoform 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

435-445

Informations de copyright

Copyright © 2019 The Author(s).

Auteurs

Roselyne Castonguay (R)

Acceleron Pharma, Cambridge, Massachusetts rcastonguay@acceleronpharma.com.

Jennifer Lachey (J)

Acceleron Pharma, Cambridge, Massachusetts.

Samantha Wallner (S)

Acceleron Pharma, Cambridge, Massachusetts.

Jamie Strand (J)

Acceleron Pharma, Cambridge, Massachusetts.

Katia Liharska (K)

Acceleron Pharma, Cambridge, Massachusetts.

Abigail E Watanabe (AE)

Acceleron Pharma, Cambridge, Massachusetts.

Marishka Cannell (M)

Acceleron Pharma, Cambridge, Massachusetts.

Monique V Davies (MV)

Acceleron Pharma, Cambridge, Massachusetts.

Dianne Sako (D)

Acceleron Pharma, Cambridge, Massachusetts.

Megan E Troy (ME)

Acceleron Pharma, Cambridge, Massachusetts.

Lavanya Krishnan (L)

Acceleron Pharma, Cambridge, Massachusetts.

Aaron W Mulivor (AW)

Acceleron Pharma, Cambridge, Massachusetts.

Huiming Li (H)

Acceleron Pharma, Cambridge, Massachusetts.

Sarah Keates (S)

Acceleron Pharma, Cambridge, Massachusetts.

Mark J Alexander (MJ)

Acceleron Pharma, Cambridge, Massachusetts.

R Scott Pearsall (RS)

Acceleron Pharma, Cambridge, Massachusetts.

Ravi Kumar (R)

Acceleron Pharma, Cambridge, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH